Brain Metastases in Differentiated Thyroid Carcinoma: Clinical Features, Treatment Outcomes, and the Role of Radioiodine Therapy
Clinical Endocrinology · 2026
DOI: 10.1111/cen.70142 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Endocrinology, 2026. Verfasst von Yogita Khandelwal und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Iodine Radioisotopes, Brain Neoplasms. Die Arbeit nennt 28 Literaturangaben.
Abstract (Originalsprache)
Objective
Brain metastases (BM) in differentiated thyroid carcinoma (DTC) are rare, with reported incidence of < 1%. They are associated with significant morbidity and poor outcomes, and the role of radioiodine therapy (RAI) in their management remains uncertain. This study aimed to evaluate clinicopathological features, treatment modalities, and outcomes of patients with BM from DTC, with emphasis on RAI.
Methods
This was a retrospective single‐institutional study of 44 patients with histologically confirmed DTC and synchronous/metachronous BM. Clinicopathological, treatment, and survival data were analysed.
Results
Median age was 52.5 years at BM diagnosis. Papillary carcinoma accounted for 61.4% of cases. Extracranial metastases were present in 79.5%, most commonly in lungs and bones. At BM diagnosis, 61% had solitary and 39% had multiple lesions. Of the evaluated patients, 66% demonstrated RAI‐avid BM and received a median of 4 RAI treatments (mean cumulative activity ~23.9 GBq). Three patients achieved complete remission, including two long‐term survivors (> 100 months). The disease control rate with RAI was 64%. The median overall survival (OS) in the entire cohort was 61 months (95% CI: 21–101) from DTC diagnosis and 15 months (95% CI: 6–24) from BM diagnosis with significantly improved outcomes in younger patients. While numerically longer median OS was observed for patients having solitary BM, RAI‐avid BM, and multimodal treatment approaches, the results were statistically insignificant.
Conclusions
BM from DTC are uncommon but confer poor prognosis. Durable responses were observed with RAI in a selected subset, but no statistically significant survival advantage could be demonstrated. Individualised multimodality management is essential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India.
- Department of Nuclear Medicine, HBCH & MPMMCC, Tata Memorial Centre, Varanasi, India.
ORCID-Profile: Yogita Khandelwal, Chandrasekhar Bal
Zitieren
APA
Khandelwal, Y., Satapathy, S., & Bal, C. (2026). Brain Metastases in Differentiated Thyroid Carcinoma: Clinical Features, Treatment Outcomes, and the Role of Radioiodine Therapy. Clinical Endocrinology. https://doi.org/10.1111/cen.70142
Vancouver
Khandelwal Y, Satapathy S, Bal C. Brain Metastases in Differentiated Thyroid Carcinoma: Clinical Features, Treatment Outcomes, and the Role of Radioiodine Therapy. Clinical Endocrinology. 2026. doi:10.1111/cen.70142
BibTeX
@article{Khandelwal2026,
author = {Khandelwal, Yogita and Satapathy, Swayamjeet and Bal, Chandrasekhar},
title = {Brain Metastases in Differentiated Thyroid Carcinoma: Clinical Features, Treatment Outcomes, and the Role of Radioiodine Therapy},
journal = {Clinical Endocrinology},
year = {2026},
doi = {10.1111/cen.70142}
}
EUVIMED